Programa Integrativo Traslacional | Nanodelivery
Nanomedicine and Drug Delivery
María José Alonso Fernández
Group Leader | Full professor
mariaj.alonso@usc.es
Labs: P5L1, P5L2, P6L1, P6L2
Área de conocimiento
We are particularly involved in the translation of ideas from the university through novel pharmaceutical technology. Our scientific research involves the use of nanotechnologies to design innovative nanomedicines. We develop novel nanostructured materials intended to transport drugs and antigens across biological barriers and deliver them to the target tissue. We are specialized in the association of delicate molecules, including peptides, siRNA, and antigens to these nanocarriers.
-
Líneas de investigación
-
Miembros
-
Publicaciones seleccionadas
-
Resultados seleccionados
-
Proyectos
-
Patentes
Líneas de investigación
- Oral Peptide Delivery: Creating new conceptual approaches for delivering protein drugs and genes across complex barriers in the body, such as the nasal, ocular and intestinal barriers.
- Nanovaccines: Designing and developing new nanocarriers for antigen delivery and investigating their adjuvant properties (nanovaccines).
- Oncology (Precision nanomedicine and theragnostics): Designing and developing nano-oncological therapies consisting of multifunctional nanocarriers targeted to the tumor cells, the tumor associated macrophages. (TAM) and the lymphatic vessels
- Regenerative medicine: patient centred solutions for the personalised regeneration of osteoarticular tissues.
- Brain RNA Delivery: the goal is to provide an RNA-based therapy perspective for neurodegenerative diseases targeting the direct cause of the disease instead of its symptoms in the midterm.
- Covid-19: Development of nanotherapies for the prevention and treatment of Covid 19.
Overall, our research has led to the development of potential new treatments in diverse therapeutic areas, with particular emphasis in cancer, ocular diseases, skin diseases, diabetes and obesity, and, in general, autoimmune diseases. In addition, we are currently devoting significant efforts to the development of needle-free HIV vaccine.
All our research activity is part of multidisciplinary consortia, in which experts in various fields and industries are involved
Miembros
Dolores Torres López
Full Professor
dolores.torres@usc.es
Anna Abbadessa
Research Associate
anna.abbadessa@usc.es
Brenda Velasco Rodríguez
Postdoctoral research associate
brenda.velasco.rodriguez@usc.es
Eva González Freire
Postdoctoral research associate
evagonzalez.freire@usc.es
Lucía Sanjurjo Bouza
Postdoctoral research associate
l.sanxurxo@gmail.com
Marta Martínez Guitián
Margarita Salas Postdoctoral Fellowship
m.martinez.guitian@gmail.com
Virna Margarita Martín Giménez
Postdoctoral research associate
virnamargarita.martin.gimenez@usc.es
Publicaciones seleccionadas
Intracellular Delivery of an Antibody Targeting Gasdermin-B Reduces HER2 Breast Cancer Aggressiveness
Nose-to-brain delivery of enveloped RNA - cell permeating peptide nanocomplexes for the treatment of neurodegenerative diseases
Nanotechnologies for the delivery of biologicals: Historical perspective and current landscape
Carboxymethyl‑β‑glucan/chitosan nanoparticles: new thermostable and efficient carriers for antigen delivery
Resultados seleccionados
Proyectos
UE project(s)
Targeting Circadian Clock Dysfunction in Alzheimer’s Disease (TClock4AD)
PI: María Jose Alonso Fernández
Marie Skłodowska-Curie – ITNMarie Skłodowska-Curie Actions (MSCA)Contracts Agreements Services
Servizo de asesoría a Cantabria Labs para a implementación do diseño e desenvolvemento de produto.
PI: María Josefa Alonso Fernández
INDUSTRIAL FARMACEUTICA CANTABRIA, SAPatentes
Polyarginine nanocapsules
Application Nº: ES20090001098 20090422
Protamine nanocapsules
Application Nº: P201231956
Saccharide nanocompositions for vaccine release
Application Nº: WO2012ES70470 20120626
Nanoparticulate systems prepared from sorbitan esters
Application Nº: WO2012ES70774 20121108
Polysialic acid drug delivery systems and methods
Application Nº: P201731277
Nanosistemas con complejos
Application Nº: P201830729
Intracellular delivery of antiKRAS antibodies
Application Nº: EP19172120.8
Nanopartículas con interiores protegidos, y métodos de uso de las mismas
Application Nº: P201631221
Intracellular delivery of anti-KRAS antibodies formulated into nanocapsules
Application Nº: EP19172120
Nanocapsules of protamine
Application Nº: US9642816B2
Nanoparticles with protected interiors and methods of use thereof
Application Nº: US10,471,020 B2
Nanocapsules with a polymer shell
Application Nº: EP2664324 B1
Nanocapsule of Protamine
Application Nº: EP2932965 B1
Chitosan and ciclodextrine nanoparticles
Application Nº: P200501331 Licenced.
Nanoparticles of polyoxyethylenated derivatives
Application Nº: WO2005002550A1
Nanoparticles of chitosan and polyethyleneglycol as a system for the administration of biologically-active molecules
Application Nº: WO2006097558A3
Nanocapsular formulation of active pharmaceutical ingredients
Application Nº: WO2015189387A1